Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Caselli, R. J.
Right arrow Articles by Thibodeau, S. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Caselli, R. J.
Right arrow Articles by Thibodeau, S. N.
Neurology 1999;53:201
© 1999 American Academy of Neurology


Articles

Preclinical memory decline in cognitively normal apolipoprotein E–{epsilon}4 homozygotes

R. J. Caselli, MD, N. R. Graff–Radford, MD, E. M. Reiman, MD, A. Weaver, MS, D. Osborne, PhD, J. Lucas, PhD, A. Uecker, PhD and S. N. Thibodeau, MD

From the Department of Neurology (Dr. Caselli), the Division of Biostatistics (A. Weaver), and the Division of Psychology (Dr. Osborne), Mayo Clinic Scottsdale, AZ; the Department of Neurology (Drs. Graff–Radford and Lucas), Mayo Clinic Jacksonville, FL; the Department of Psychiatry (Dr. Reiman), University of Arizona and Samaritan Positron Emission Tomography Center, Phoenix, AZ; the Arizona Research Laboratories Division of Neural Systems, Memory, and Aging (Dr. Ueker), University of Arizona, Tucson, AZ; and the Department of Laboratory Medicine (Dr. Thibodeau), Mayo Clinic, Rochester, MN.

Address correspondence and reprint requests to Dr. Richard J. Caselli, Department of Neurology, Mayo Clinic Scottsdale, 13400 East Shea Boulevard, Scottsdale, AZ 85259.

OBJECTIVE: To determine, in a cross-sectional evaluation of nondemented individuals, if age-related memory decline is influenced by apolipoprotein E (apoE) genotype.

BACKGROUND: The apoE-4 allele is an important risk factor for AD. PET in cognitively normal apoE-4 carriers (mean age, 56 years) shows reduced cerebral metabolism suggestive of very early AD that precedes clinically evident memory loss or MRI-based hippocampal atrophy.

METHODS: Tests of immediate and delayed recall (primary outcome measures) and other neuropsychological measures (secondary outcome measures) were given to three genetically defined groups of cognitively normal individuals (age, 49 to 69 years) including apoE-4 homozygotes (n = 25), apoE-4 heterozygotes (n = 25, all {epsilon}3/4), and apoE-4 noncarriers (n = 50). Groups were matched for age, gender, and educational background. Cross-sectional comparisons between the genetic subgroups of the relationship between age and test score were performed for each neuropsychological measure.

RESULTS: There were no intergroup differences in mean scores on any neuropsychological measure, but tests sensitive to immediate and delayed recall showed a significant negative correlation with age in the apoE-4 homozygote group relative to the noncarrier group.

CONCLUSION: Consistent with previous neuropsychological studies of early AD, this cross-sectional study suggests that age-related memory decline occurs earlier in cognitively healthy apoE-4 homozygotes than in apoE-4 heterozygotes and noncarriers, and precedes clinically detectable AD.




This article has been cited by other articles:


Home page
J. Neurosci.Home page
S. C. Johnson, T. W. Schmitz, M. A. Trivedi, M. L. Ries, B. M. Torgerson, C. M. Carlsson, S. Asthana, B. P. Hermann, and M. A. Sager
The influence of Alzheimer disease family history and apolipoprotein E epsilon4 on mesial temporal lobe activation.
J. Neurosci., May 31, 2006; 26(22): 6069 - 6076.
[Abstract] [Full Text] [PDF]


Home page
BrainHome page
A. L. W. Bokde, P. Lopez-Bayo, T. Meindl, S. Pechler, C. Born, F. Faltraco, S. J. Teipel, H.-J. Moller, and H. Hampel
Functional connectivity of the fusiform gyrus during a face-matching task in subjects with mild cognitive impairment
Brain, May 1, 2006; 129(5): 1113 - 1124.
[Abstract] [Full Text] [PDF]


Home page
Arch NeurolHome page
D. P. Devanand, G. H. Pelton, D. Zamora, X. Liu, M. H. Tabert, M. Goodkind, N. Scarmeas, I. Braun, Y. Stern, and R. Mayeux
Predictive Utility of Apolipoprotein E Genotype for Alzheimer Disease in Outpatients With Mild Cognitive Impairment
Arch Neurol, June 1, 2005; 62(6): 975 - 980.
[Abstract] [Full Text] [PDF]


Home page
J. Neurol. Neurosurg. PsychiatryHome page
L Mosconi, K Herholz, I Prohovnik, B Nacmias, M T R De Cristofaro, M Fayyaz, L Bracco, S Sorbi, and A Pupi
Metabolic interaction between ApoE genotype and onset age in Alzheimer's disease: implications for brain reserve
J. Neurol. Neurosurg. Psychiatry, January 1, 2005; 76(1): 15 - 23.
[Abstract] [Full Text] [PDF]


Home page
J. Neuropsychiatry Clin. Neurosi.Home page
R. J. Caselli, E. M. Reiman, J. G. Hentz, D. Osborne, and G. E. Alexander
A Distinctive Interaction Between Chronic Anxiety and Problem Solving in Asymptomatic APOE e4 Homozygotes
J Neuropsychiatry Clin Neurosci, August 1, 2004; 16(3): 320 - 329.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
R. J. Caselli, E. M. Reiman, D. Osborne, J. G. Hentz, L. C. Baxter, J. L. Hernandez, and G. G. Alexander
Longitudinal changes in cognition and behavior in asymptomatic carriers of the APOE e4 allele
Neurology, June 8, 2004; 62(11): 1990 - 1995.
[Abstract] [Full Text] [PDF]


Home page
J. Neurol. Neurosurg. PsychiatryHome page
L Mosconi, B Nacmias, S Sorbi, M T R De Cristofaro, M Fayazz, A Tedde, L Bracco, K Herholz, and A Pupi
Brain metabolic decreases related to the dose of the ApoE e4 allele in Alzheimer's disease
J. Neurol. Neurosurg. Psychiatry, March 1, 2004; 75(3): 370 - 376.
[Abstract] [Full Text] [PDF]


Home page
AJGPHome page
H. Lavretsky, L. Ercoli, P. Siddarth, S. Bookheimer, K. Miller, and G. Small
Apolipoprotein {epsilon}4 Allele Status, Depressive Symptoms, and Cognitive Decline in Middle-Aged and Elderly Persons Without Dementia
Am J Geriatr Psychiatry, December 1, 2003; 11(6): 667 - 673.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
M. Buttini, G.-Q. Yu, K. Shockley, Y. Huang, B. Jones, E. Masliah, M. Mallory, T. Yeo, F. M. Longo, and L. Mucke
Modulation of Alzheimer-Like Synaptic and Cholinergic Deficits in Transgenic Mice by Human Apolipoprotein E Depends on Isoform , Aging, and Overexpression of Amyloid beta Peptides But Not on Plaque Formation
J. Neurosci., December 15, 2002; 22(24): 10539 - 10548.
[Abstract] [Full Text] [PDF]


Home page
J. Med. Genet.Home page
A G Yip, C Brayne, D Easton, and D C Rubinsztein
Apolipoprotein E4 is only a weak predictor of dementia and cognitive decline in the general population
J. Med. Genet., September 1, 2002; 39(9): 639 - 643.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
R. P. Friedland, T. Fritsch, K. A. Smyth, E. Koss, A. J. Lerner, C. H. Chen, G. J. Petot, and S. M. Debanne
Patients with Alzheimer's disease have reduced activities in midlife compared with healthy control-group members
PNAS, March 1, 2001; (2001) 61002998.
[Abstract] [Full Text]


Home page
Am. J. Neuroradiol.Home page
E. D. Bigler, C. M. Lowry, C. V. Anderson, S. C. Johnson, J. Terry, and M. Steed
Dementia, Quantitative Neuroimaging, and Apolipoprotein E Genotype
AJNR Am. J. Neuroradiol., November 1, 2000; 21(10): 1857 - 1868.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
P. M. Greenwood, T. Sunderland, J. L. Friz, and R. Parasuraman
Genetics and visual attention: Selective deficits in healthy adult carriers of the varepsilon 4 allele of the apolipoprotein E gene
PNAS, October 10, 2000; 97(21): 11661 - 11666.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
B. J. Small, A. B. Graves, C. L. McEvoy, F. C. Crawford, M. Mullan, and J. A. Mortimer
Is APOE-{epsilon}4 a risk factor for cognitive impairment in normal aging?
Neurology, June 13, 2000; 54(11): 2082 - 2088.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
M. G. Dik, C. Jonker, L. M. Bouter, M. I. Geerlings, G. J. van Kamp, and D. J. H. Deeg
APOE-{epsilon}4 is associated with memory decline in cognitively impaired elderly
Neurology, April 11, 2000; 54(7): 1492 - 1497.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
R. P. Friedland, T. Fritsch, K. A. Smyth, E. Koss, A. J. Lerner, C. H. Chen, G. J. Petot, and S. M. Debanne
Patients with Alzheimer's disease have reduced activities in midlife compared with healthy control-group members
PNAS, March 13, 2001; 98(6): 3440 - 3445.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by AAN Enterprises, Inc.